Peakdale Molecular Limited, a UK-based provider of drug discovery services to the pharmaceutical and biotech industries and part of the Concept Life Sciences Group has signed a collaboration agreement with computational chemistry company, Cresset. By partnering with Cresset, Peakdale has further extended its integrated drug discovery offering.
Cresset delivers software and contract research services which help chemists discover, design and optimise the best small molecules for their project. Cresset’s software uses 3D molecular electrostatics and shape to shed light on the properties and behaviours of chemical structures and, crucially, to understand the key interactions which underpin biological behaviour. Whilst Cresset software allows unique insights into protein-ligand interactions, it is the expertise of the Cresset scientists in interpreting the data and deriving knowledge for future compound design that is so valuable. These services are based on the research into virtual screening technology undertaken by Cresset founder, Dr Andy Vinter.
Commenting on the partnership Dr David Bardsley, Commercial Director at Cresset said: “Global discovery organisations today work with a number of service providers to enable their research efforts. However, there is an important balance to be found between approaching a single integrated service provider and companies trying to select the best expertise for each aspect of their programmes. We are delighted to be working with Peakdale and look forward to delivering our partnership to clients across the world.”
Dr Paul Doyle of Peakdale continued “Cresset’s reputation and experience in science and the breadth of understanding in computational problems makes them the ideal collaborator in the fields we are working. By adding their services and importantly , expertise, to the Peakdale offering we have further broadened a key element in our integrated drug discovery offering with world leading science.”
About Cresset Discovery Services
Cresset Discovery Services offers a powerful combination of human expertise, computational biology and computational chemistry approaches to solve high-value problems in drug discovery. We have been offering services for over a decade and, during that time, have successfully completed over 200 projects for our clients. Together our scientists have more than 150 years of combined industrial experience across a broad range of targets and therapeutic areas. Our proven commercial software and our cutting-edge research software deliver key insights and impactful results. For more information, please visit www.cresset-group.com/discovery-services.
About Peakdale Molecular
Peakdale Molecular provides excellence in chemistry as standard across many areas of research – in particular as a part of the Discovery and Development Division of Concept Life Sciences Group – we are a leading UK-based CRO delivering a vast array of high quality services for early phase discovery. Peakdale offers a range of services to accelerate clients’ discovery needs which can be tailored as necessary to meet specific requirements. The company operates a comprehensive suite of services for hit-to-lead and lead optimisation studies, including early stage ADME. Having two UK locations, Chapel-en-le-Frith (near Manchester) and Sandwich (Kent), Peakdale has assembled an enviable array of assets for small molecule discovery including state of the art chemistry laboratories, purpose-built biology labs with cell culture facilities, automated purification and analytical capabilities Together with a scientific team of over 100 scientists with experience of over eighty drug targets in multiple therapeutic areas Peakdale is an ideal partner to deliver on integrated drug discovery programmes. Peakdale offers a variety of customised commercial frameworks, from simple fee-for-service through to long-term FTE projects and are trusted by major Pharma & Biotech companies. For more information, please visit http://www.peakdale.co.uk/